Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 4/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29178 | 1.00 | TDP1 (0.45) | TDP1CYP3A4ESR1ESR2TAAR1 | |
| SCHEMBL4249541 | 1.00 | TDP1 (0.45) | TDP1CYP3A4ESR1ESR2TAAR1 | |
| SCHEMBL12584889 | 1.00 | TDP1 (0.45) | TDP1CYP3A4ESR1ESR2TAAR1 | |
| SCHEMBL31588 | 1.00 | TDP1 (0.45) | TDP1CYP3A4ESR1ESR2TAAR1 | |
| SCHEMBL18832827 | 1.00 | TDP1 (0.45) | TDP1CYP3A4ESR1ESR2TAAR1 | |
| SCHEMBL30366682 | 0.97 | TDP1 (0.43) | TDP1CYP3A4ESR1ESR2TAAR1 | |
| Hydrochloric Acid SCHEMBL10627881 | 0.95 | TDP1 (0.41) | TDP1CYP3A4ESR1ESR2TAAR1 | |
| SCHEMBL10627887 | 0.90 | TDP1 (0.38) | TDP1CYP3A4ESR1ESR2 | |
| SCHEMBL14713495 | 0.89 | TDP1 (0.41) | TDP1CYP3A4ESR1ESR2TAAR1 | |
| SCHEMBL18294158 | 0.89 | TDP1 (0.41) | TDP1CYP3A4ESR1ESR2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 364 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074854-A1 | PROCESS FOR THE SELECTIVE CATALYTIC HYDROGENATION OF DIENONES | BASF SE (DE) | 2025-03-06 | — | — | US | claimed |
| CN-119462502-A | Tenapanol Process for the preparation of intermediates | 杭州善礼生物医药科技有限公司 | 2025-02-18 | — | — | CN | claimed |
| EP-4463433-A2 | PROCESS FOR THE SELECTIVE CATALYTIC HYDROGENATION OF DIENONES | BASF SE (DE) | 2024-11-20 | — | — | EP | claimed |
| WO-2023137133-A2 | PROCESS FOR THE SELECTIVE CATALYTIC HYDROGENATION OF DIENONES | BASF SE (DE) | 2023-07-20 | — | — | WO | claimed |
| US-11390585-B2 | Quaternary heteroatom containing compounds | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-07-19 | — | — | US | claimed |
| EP-3998271-A2 | PENTACYCLIC DIAMIDES WITH OPTOELECTRONIC APPLICATIONS, METHODS TO PRODUCE THEM AND USES THEREOF | UNIVERSIDADE NOVA DE LISBOA (PT) | 2022-05-18 | — | — | EP | claimed |
| CN-111909065-B | Method for alpha-methylation of aryl benzyl sulfone compound | 浙江工业大学 | 2022-04-22 | — | — | CN | claimed |
| US-8487109-B2 | Process for the palladium-catalyzed coupling of terminal alkynes with aryl tosylates | SANOFI (FR) | 2013-07-16 | — | — | US | claimed |
| US-8420812-B2 | Process for the palladium-catalyzed coupling of terminal alkynes with heteroaryl tosylates and heteroaryl benzenesulfonates | SANOFI (FR) | 2013-04-16 | — | — | US | claimed |
| EP-2176203-B1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH ARYL TOSYLATES | SANOFI SA (FR) | 2011-08-10 | — | — | EP | claimed |
| US-20070203195-A1 | Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals | PRAKTIKATALYST PHARMA, LLC | 2007-08-30 | — | — | US | claimed |
| EP-1747224-A1 | COMPLEXES OF RUTHENIUM WITH 2-(AMINOMETHYL)PYRIDINES AND PHOSPHINES, THEIR PREPARATION AND USE AS CATALYSTS | Universita' Degli Studi di Udine (IT) | 2007-01-31 | — | — | EP | claimed |
| WO-2005105819-A1 | COMPLEXES OF RUTHENIUM WITH 2-(AMINOMETHYL)PYRIDINES AND PHOSPHINES, THEIR PREPARATION AND USE AS CATALYSTS | UNIVERSITA' DEGLI STUDI DI UDINE (IT) | 2005-11-10 | — | — | WO | claimed |
| US-6005148-A | COMPRISING SUPPORT, ANCHORING AGENT SUCH AS HETEROPOLY ACID OR ANION, AND METAL COMPLEX USEFUL IN HYDROGENATION OF SUBSTITUTED UNSATURATED ACIDS AND ESTERS | SETON HALL UNIVERSITY (US) | 1999-12-21 | — | — | US | claimed |
| EP-0631571-B1 | PREPARATION OF OPTICALLY ACTIVE HYDRAZINES AND AMINES | DU PONT (US) | 1997-06-04 | — | — | EP | claimed |
| US-5631397-A | MULTISTAGE REACTION USING CATALYTIC HYDROGEN REACTION IN PRESENCE OF METAL PHOSPHOROUS CATALYST | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1997-05-20 | — | — | US | claimed |
| US-5426223-A | Hydrogenation of n-acyl hydrazones in presence of catalyst comprising complex pf transition metal bonded to phosphine ligands | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-06-20 | — | — | US | claimed |
| US-5250731-A | Asymmetric hydrogenation of N-acylhydrazones to N-acylhydrazines in presence of chiral phospholane complex | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-10-05 | — | — | US | claimed |
| WO-1993019040-A1 | PREPARATION OF OPTICALLY ACTIVE HYDRAZINES AND AMINES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-09-30 | — | — | WO | claimed |
| US-4654176-A | Sulphonated chiral phosphines, their preparation and their use | RHONE-POULENC SANTE (FR) | 1987-03-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074854-A1 | PROCESS FOR THE SELECTIVE CATALYTIC HYDROGENATION OF DIENONES | PRDX5, DHX15, NDUFS5 | TDP1 2252/4885CYP3A4 49/4885ESR1 3649/4885 |
| US-11390585-B2 | Quaternary heteroatom containing compounds | SDHA, NQO1, SDHB | TDP1 4001/4885CYP3A4 57/4885ESR1 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.